ArticlePharmaceutics2020
Evaluation of CpG-ODN-Adjuvanted
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Applications of virus-like particles in the prevention of protozoan parasite infection.Nanomedicine (London, England) · 2025Review
- Article
- Heterologous immunization targeting the CST1 antigen confers better protection than ROP18 in mice.Nanomedicine (London, England) · 2024Article
- Recent progress in vaccine development targeting pre-clinical human toxoplasmosis.Parasites, hosts and diseases · 2023Article
- Protective mucosal and systemic immunity induced by virus-like particles expressing Toxoplasma gondii cyst wall protein.PloS one · 2023Article
- The Immunomodulation Role of Vaginal Microenvironment On Human Papillomavirus Infection.Galen medical journal · 2023Article
- Protection Induced by Vaccination with Recombinant Baculovirus and Virus-like Particles ExpressingVaccines · 2022Article
- Orally Administrated Recombinant Vaccinia Virus Displaying ROP4 Induces Protection againstVaccines · 2022Article
- Passive Immunity and Antibody Response Induced byVaccines · 2021Article
- Advances inVaccines · 2021Review
- Mucosal Administration of Recombinant Baculovirus DisplayingFrontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Successful vaccines against specific pathogens often require multiple immunizations and adjuvant usage. Yet, assessing the protective efficacy of different immunization regimens with adjuvanted Toxoplasma gondii vaccines remains elusive. In this study, we investigated the vaccine efficacy induced by CpG-ODN-adjuvanted T. gondii virus-like particles (VLPs) after challenge infection with T. gondii (ME49) in mice (BALB/c) upon one, two, and three immunizations. Immunization with adjuvanted T. gondii VLPs induced higher levels of T. gondii-specific IgG and/or IgA antibody responses, germinal center (GC) B cells, total B cells, and CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.